Full Breakdown
Senator Hawley Calls for DOJ Investigation into Mifepristone Manufacturer
4/14/2026, 10:39:53 PM
Overview of the Investigation Request
Senator Josh Hawley, a Republican from Missouri, has urged the Department of Justice (DOJ) to investigate Danco Laboratories, the manufacturer of the abortion drug mifepristone. In a letter to Acting Attorney General Todd Blanche, Hawley expressed concerns regarding the safety of mifepristone, which he claims is associated with higher rates of adverse effects than reported. He highlighted that mifepristone accounts for over 70% of abortions in the United States, a figure that has increased significantly in recent years.
Concerns Raised by Senator Hawley
Hawley's letter emphasized the lack of transparency surrounding Danco Laboratories, noting that the company has a corporate structure that is "largely shielded from public view." He pointed out that Danco was incorporated in the Cayman Islands and operates with minimal public information, employing fewer than 20 individuals and using a P.O. Box for its address. The senator criticized the company's practices, suggesting that it has taken extreme measures to protect itself from liability.
In his correspondence, Hawley referenced a study conducted by the Ethics and Public Policy Center, which indicated that 10.93% of women experienced serious adverse events, such as sepsis or hemorrhaging, within 45 days following a mifepristone abortion. The senator called for a comprehensive investigation into Danco's regulatory compliance, marketing practices, and safety disclosures.
Official Statements & Responses
The Food and Drug Administration (FDA) has classified mifepristone as safe but acknowledged receiving reports of serious adverse events associated with its use. As of December 31, 2024, there have been 36 reported deaths linked to mifepristone since its approval in 2000, including cases of ectopic pregnancy and severe systemic infections. Hawley urged the DOJ to ensure that Danco complies with all relevant laws and regulations, emphasizing the need for accountability in the pharmaceutical industry.
Criticism & Opposition
While Hawley's concerns reflect a significant viewpoint among pro-life advocates, critics argue that the safety of mifepristone has been established through extensive research and regulatory review. Proponents of abortion rights contend that the calls for investigation may be politically motivated and could undermine access to safe abortion services.
Conflicting Reports & Gaps
There is a discrepancy in the reported safety of mifepristone, with the FDA maintaining its safety profile while Hawley cites studies indicating higher rates of adverse events. The ongoing debate highlights the need for further investigation into the drug's safety and the practices of its manufacturer.
What's Next
The DOJ has yet to respond to Hawley's request for an investigation. As the situation develops, further scrutiny of Danco Laboratories and its practices may unfold, potentially impacting the availability and regulation of mifepristone in the United States.
